

FY2023 JULY 1, 2022 - JUNE 30, 2023

Global Cancer Advancements in Immunotherapy Research

See how the Cancer Research Institute (CRI) is transforming the lives of cancer patients on a global scale.



OUR MISSION

SAVE MORE LIVES by fueling the discovery and development of powerful immunotherapies for all cancers.

Ranked among the top 5% of U.S. rated charities









01 / IMPACT

Fueling the Next Wave of Discovery

CRI funds scientists from around the world to advance new avenues of discovery, new technologies, and new ways to analyze and share data about our immune system and it's power to outsmart cancer. \$515M

invested in CRI scientists worldwide since 1953

\$28.7M

invested in research grants and fellowships in FY2023

12 new FDA approvals

28

cancers now treatable with immunotherapy thanks to the work of CRI

02 / CANCERS


Redefining Immunotherapy Success

CRI scientists are accelerating discovery thanks to new technologies that marry data science, bioinformatics, and cancer immunology. To date, there are 4M patients eligible for immunotherapy treatments worldwide.

03 / PEOPLE

Empowering the Best Scientists

CRI's research is guided by our prestigious Scientific Advisory Council, led by 2018 Nobel Laureate James P. Allison, PhD. Our scientists are leading the charge to advance immunotherapy discovery and shaping the future of the field.



300 PUBLICATIONS

04 / RESEARCH

Recognizing Research Excellence

CRI-funded scientists had 300 publications of news-worthy research in top-tier peer-reviewed academic journals this year.

05 / DISCOVERY

Unleashing Science with the Power of Data

CRI funded a clinical trial spearheaded by Dr. Valsamo "Elsa" Anagnostou, MD, PhD, from Johns Hopkins, investigating ctDNA technology's potential. This method, through a blood draw, provides valuable insights into tumor genetics and activity. The trial showed that ctDNA analysis yielded faster, more accurate responses and enhanced predictions for long-term patient outcomes.

